WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announce…
Author: Business Wire
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (“GenSight Biologics” or the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for ret…
GenSight Biologics Announces its 2024 Financial Calendar
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics annonce son calendrier financier pour 2024
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodé…
EyeCare Partners Announces New Refractive Cataract Anterior Segment Fellowship and Launch of ECP Foundation
ST. LOUIS–(BUSINESS WIRE)– #ASCRS–EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, continues to advance leadership and research at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting…
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary…
Wearing Glasses Boosts Income by a Third in Low-Income Communities, Finds Landmark New Study
NEW YORK–(BUSINESS WIRE)–A pair of reading glasses increases the earnings of people in low- income communities by 33% according to new research. A new randomised controlled trial, published today, finds that the provision of reading glasses improves …
Southern California College of Optometry Celebrates 120 Years of Educational and Clinical Excellence
FULLERTON, Calif.–(BUSINESS WIRE)–Marshall B. Ketchum University (MBKU), an independent, private, non-profit, accredited educational institution headquartered in Fullerton, Calif. proudly celebrates the 120th anniversary of its Southern California Co…
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
SAN DIEGO–(BUSINESS WIRE)–LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, t…
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the U….
West Point Optical Group, LLC and Verséa Ophthalmics, Inc. Announce Partnership Supply Agreement for BIOVANCE®and BIOVANCE® 3L Ocular
MASON, Ohio & TAMPA, Fla.–(BUSINESS WIRE)– #POCdiagnostics–West Point Optical Group, LLC (“WPOG”), providing quality patient care by developing experienced, well-rounded vision health teams within its 86 Pearle Vision stores, and Verséa Ophthalmics,…
Samenvatting: Nordic Group B.V. Nordic Pharma, Inc. (V.S.) presenteert gegevens over LACRIFILL® Canalicular Gel, een nieuwe behandeling voor droge ogen, op de jaarlijkse bijeenkomst van de American Society of Cataract and Refractive Surgery
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc., een dochteronderneming van Nordic Group B.V., zal gegevens presenteren over LACRIFILL® Canalicular Gel, een nieuwe therapie voor droge-ogensymptomen, tijdens de jaarlijkse bijeenkomst van de American S…
Nordic Group B.V. präsentiert über ihre Tochtergesellschaft Nordic Pharma, Inc. (U.S.) auf der Jahrestagung der American Society of Cataract and Refractive Surgery Daten zu LACRIFILL® Canalicular Gel, einer neuartigen Therapie für trockene Augen
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc., eine Tochtergesellschaft der Nordic Group B.V., wird während der Jahrestagung der American Society of Cataract and Refractive Surgery (ASCRS) vom 5. bis 8. April 2024 in Boston, MA, Daten zum LACRIFILL…
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
SAN DIEGO–(BUSINESS WIRE)–LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in peopl…
Riassunto: Nordic Group B.V., tramite la sua affiliata Nordic Pharma, Inc. (USA), presenterà i dati sul gel canalicolare LACRIFILL®, una nuova terapia per la sindrome dell'occhio secco, al meeting annuale dell'American Society of Cataract and Refractive Surgery
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc., una affiliata di Nordic Group B.V., presenterà i dati relativi al gel canalicolare LACRIFILL®, una nuova terapia per la sindrome dell’occhio secco, durante il meeting annuale dell’American Society of C…
Resumen: Nordic Group B.V. A través de su filial Nordic Pharma, Inc. (EE.UU.), presentará información sobre el gel canalicular LACRIFILL®, un nuevo tratamiento para el ojo seco, en el encuentro anual de la American Society of Cataract and Refractive Surgery
BERWYN, Pensilvania–(BUSINESS WIRE)–Nordic Pharma, Inc, filial de Nordic Group B.V., presentará información sobre el gel LACRIFILL®, un novedoso tratamiento para los síntomas del ojo seco, durante el encuentro anual de la American Society of Cataract…
Par l’intermédiaire de sa filiale Nordic Pharma Inc. (États-Unis), Nordic Group B.V. présentera des données sur le gel canaliculaire LACRIFILL, une nouvelle thérapie pour la sécheresse oculaire, lors de la réunion annuelle de l’American Society…
BERWYN, Pennsylvanie–(BUSINESS WIRE)– Par l’intermédiaire de sa filiale Nordic Pharma Inc. (États-Unis), Nordic Group B.V. présentera des données sur le gel canaliculaire LACRIFILL, une nouvelle thérapie pour la sécheresse oculaire, lors de la réuni…
Toku Appoints Former Google Head of Cardiovascular Health as Chief Health Officer
SAN DIEGO–(BUSINESS WIRE)–Toku is delighted to announce the appointment of Professor Michael V. McConnell, MD, MSEE to the role of Chief Health Officer. Professor McConnell’s former roles include Director of Advanced Cardiovascular Imaging and Preven…
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc. will be presenting data on LACRIFILL® Canalicular Gel during the ASCRS Annual Meeting in Boston, MA on April 5-8, 2024.
Aurion Biotech to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
SEATTLE, CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2024 American Society of Cataract…